Denise Mann is a freelance health writer based in New York. She specializes in medicine and healthcare, exploring topics such as dermatology, wellness programs, and the beauty industry, with a focus on aging and longevity. Denise's work has been featured in numerous outlets, including HealthDay News, Reader's Digest, and BuzzFeed News.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Denise Mann's coverage predominantly focuses on healthcare, pharmaceuticals, and scientific topics related to dermatology and skin conditions. The majority of her articles cite data or are based on press releases. She appears to be interested in reporting on the latest medical research, FDA approvals, and developments within the field of skincare.
When reaching out to Denise Mann with pitches or expert commentary, consider offering access to new research findings, exclusive insights into clinical trials for dermatological treatments or FDA approval processes. Providing access to experts who can offer unique perspectives on emerging trends in dermatology and skin care could also be well received by Denise.
Given that there is no specified geographic focus for Denise Mann's work, she may cover global developments within dermatology and skin care fields.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Denise Mann
Zumilokibart (APG777, Apogee Therapeutics, Inc.) met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe atopic dermatitis (AD), according to positive 16-week data from Part B of the Phase 2 APEX clinical trial. Fully 65.9% of patients treated with mid-dose zumilokibart achieved Eczema Area and Severity Index (EASI)-75 (41.9% placebo adjusted). […]
By: Denise Mann
Purified Candida albicans Antigen (Candin, Nielsen BioSciences) showed complete resolution of the injected wart without recurrence over 12 weeks and met key secondary endpoints, according to a Phase 3 clinical trial. The Company expects to file for approval with the U.S. Food and Drug Administration (FDA) in the second half of 2026. The topline results […]
Adults with AD, particularly those with childhood onset, report significantly greater limitations in their educational and professional choices, with up to 38% of childhood-onset patients reporting career restrictions and more than 36% reporting constrained study choices, compared to individuals whose disease began in adulthood, a new study in the Journal of Investigative Dermatology (JID) shows. This cross-sectional […]
Rubedo's RLS-1496 reduces AK by 46% at four weeks with minimal irritation, according to interim results from a Phase 1b/2a study.
By: Denise Mann
The US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) to include evidence in the guselkumab (Tremfya, Johnson & Johnson) label for the inhibition of progression of structural joint damage in adults with active psoriatic arthritis (PsA). “Joint damage associated with active psoriatic arthritis can happen as soon as six […]
Merkel cell carcinoma (MCC) patients experience fewer MCC-related recurrences and deaths after receiving pembrolizumab (Keytruda, Merck) post-surgery than those who received standard care alone, supporting a potential new adjuvant treatment option for this disease. This is the main takeaway from EA6174 or STAMP, a Phase 3 trial presented at the 2026 American Society of Clinical […]
By: Denise Mann
Does visible light from personal electronic devices cause photodamage? Henry W. Lim, MD, FAAD, President of the International League of Dermatological Societies (ILDS) and the Senior Vice President of Academic Affairs at Henry Ford Health in Detroit, MI, provides a definitive answer to this pressing question based on the findings from a two-day international consensus […]
By: Denise Mann
SkinPen and PanOxyl are teaming up for a new campaign spotlighting a holistic approach to acne care for Acne Awareness Month, which is held every June. As part of the campaign, the brands are partnering with Beverly Hills, CA-based Plastic Surgeon Michelle Lee, MD, and influencer Bridget Campbell to share both personal and professional perspectives […]
By: Denise Mann
Intismeran, a personalized melanoma vaccine, plus pembrolizumab (Keytruda, Merck) may reduce the risk of melanoma recurrence and death by 49% after five years, a new study shows. Results of the phase 2b trial, known formally as KEYNOTE-942, are being presented at the 2026 annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago, […]
By: Denise Mann
As many as 75% of psoriasis patients who respond well to interleukin (IL)-17 and IL-23 inhibitors can safely reduce their dosage, often even by half, finds a new study in The Lancet Regional Health – Europe. “These medicines are life-changing’, says Elke de Jong, Dermatologist and Professor of inflammatory skin diseases at the Radboud University […]
